Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
American Journal of Hematology|July 1, 1993
High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromesM Mittelman, D S Karcher, L A Kammerman, et al.
The American Journal of Medicine|October 1, 1975
Multiple myeloma in a patient with sickel cell anemia. Interacting effects on blood viscosityI S Anderson, K Y Yeung, D Hillman, et al.
Microvascular Research|September 1, 1987
Flow dynamics of human sickle erythrocytes in the mesenteric microcirculation of the exchange-transfused ratJ Kurantsin-Mills, H M Jacobs, P P Klug, et al.
European Journal of Clinical Investigation|January 1, 1994
Plasma and urinary leukotrienes in sickle cell disease: possible role in the inflammatory processB O Ibe, J Kurantsin-Mills, J U Raj, et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|June 1, 1975
Radiophosphate (32-PO4) incorporation into phosphatidic acid of lead-poisoned and normalred cellsM P Westerman, W N Jensen
British Journal of Haematology|August 1, 1992
Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patientsJ Kurantsin-Mills, F A Ofosu, T K Safa, et al.
The Journal of Clinical Investigation|October 1, 1978
Inhibition of erythrocyte sickling in vitro by pyridoxalJ A Kark, M P Kale, P G Tarassoff, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1989
Indium-111 oxine labeled erythrocytes: cellular distribution and efflux kinetics of the labelJ Kurantsin-Mills, H M Jacobs, R Siegel, et al.
British Journal of Haematology|July 1, 1994
Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulationJ Kurantsin-Mills, B O Ibe, C L Natta, et al.
Cancer|March 15, 1993
Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II studyB R Greenberg, R D Reynolds, C B Charron, et al.
Pageof 4